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ABSTRACT
This study was conducted to define a new maximum tolerated dose and the dose-limiting toxicity (DLT) of
melphalan and autologous hematopoietic stem cell transplantation (AHSCT) when used with the cytoprotec-
tive agent amifostine. Fifty-eight patients with various types of malignancy who were ineligible for higher-
priority AHSCT protocols were entered on a phase I study of escalating doses of melphalan beginning at 220
mg/m2 and advancing by 20 mg/m2 increments in planned cohorts of 4 to 8 patients until severe regimen-
related toxicity (RRT) was encountered. In all patients, amifostine 740 mg/m2 was given on 2 occasions before
the first melphalan dose (ie, 24 hours before and again 15 minutes before). AHSCT was given 24 hours after
the first melphalan dose. Melphalan was given in doses up to and including 300 mg/m2. Hematologic
depression was profound, although it was rapidly and equally reversible at all melphalan doses. Although
mucosal RRT was substantial, it was not the DLT, and some patients given the highest melphalan doses (ie,
300 mg/m2) did not develop mucosal RRT. The DLT was not clearly defined. Cardiac toxicity in the form of
atrial fibrillation occurred in 3 of 36 patients treated with melphalan doses >280 mg/m2 and was deemed fatal
in 1 patient given melphalan 300 mg/m2. (Another patient with a known cardiomyopathy was given melphalan
220 mg/m2 and died as a result of heart failure but did not have atrial fibrillation.) Another patient given
melphalan 300 mg/m2 died of hepatic necrosis. The maximum tolerated dose of melphalan in this setting was
thus considered to be 280 mg/m2, and 27 patients were given this dose without severe RRT. Moreover, 38
patients were evaluable for delayed toxicity related to RRT; none was noted. Tumor responses have been noted
at all melphalan doses and in all diagnostic groups, and 21 patients are alive at median day 1121 (range, day
136 to day 1923), including 16 without evidence of disease progression at median day 1075 (range, day
509 to day 1638). Amifostine and AHSCT permit the safe use of melphalan 280 mg/m2, an apparent increase
over the dose of melphalan that can be safely administered with AHSCT but without amifostine. Further studies are
needed not only to confirm these findings, but also to define the antitumor efficacy of this regimen. Finally, it
may be possible to evaluate additional methods of further dose escalation of melphalan in this setting.
© 2004 American Society for Blood and Marrow Transplantation
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kNTRODUCTION
The use of autologous hematopoietic stem cell
ransplantation (AHSCT) to abrogate prolonged he-
atologic toxicity allows a variable, but often consid- s
B&MTrable, degree of dose escalation of certain cytotoxic
gents used for cancer therapy [1]. Although the spe-
iﬁcs of dose-response curves in humans are not
nown, both experimental [2] and clinical [3] data
uggest a beneﬁt for continuously increasing doses of
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4ertain cytotoxic agents in some situations. However,
he development of severe regimen-related toxicity
RRT) [1,4] has limited further exploration of dose
ugmentation beyond that permitted by AHSCT.
A limited body of clinical evidence suggests po-
ential utility of increasing the dose of selected cyto-
oxic agents beyond the limits currently permitted
ith AHSCT but prevented by RRT. For example,
lift et al. [5] evaluated increased cumulative fraction-
ted total body irradiation doses (ie, 1575 cGy versus
he standard 1200 cGy) plus cyclophosphamide in a
andomized clinical trial for the treatment of chronic
yelogenous leukemia in the allogeneic transplant
etting. A lower actuarial relapse rate (0% versus 25%)
ut a higher nonrelapse mortality rate (34% versus
4%) led to a similar event-free survival at 4 years
66% versus 60%). Although the allogeneic setting is
ore complex than AHSCT, an important point of
his study is that a roughly 30% increase over a com-
only used radiation dose reduced relapse rates to nil.
he results of this study also emphasize that addi-
ional RRT or nonrelapse mortality must be avoided
or further dose escalation to be useful.
Similar considerations might also apply to certain
lkylating agents [2,3]. As expected, however, increas-
ng the doses of these agents also produces more
ematologic toxicity and RRT. For example, the bi-
unctional alkylating agent melphalan can usually be
iven with the use of hematopoietic growth factors in
oses up to and including 140 mg/m2 [6-8]. At higher
oses [8], AHSCT is presumably required and is al-
ost always used. Although hematologic toxicity is
hus abrogated with AHSCT, melphalan doses of 200
o 225 mg/m2 produce variable, but often severe,
ucosal RRT that is considered the dose-limiting
oxicity (DLT) [8-10].
In any case, the amelioration of RRT to allow
urther dose escalation—beyond that permitted
ith AHSCT—is a formidable undertaking because
f the considerable intrinsic RRT of most existing
egimens and the worsening of RRT anticipated
ith higher doses. Moreover, effective cytoprotec-
ion is hampered by the relative lack of broad-
pectrum cytoprotective agents; the aminothiol
mifostine is the main such agent currently available
11]. Although amifostine has been successfully used
o reduce both hematologic toxicity and RRT due
o certain chemotherapeutic drugs in conventional
oses [12], published reports in the situation of
ose-intensive chemotherapy requiring AHSCT are
ore limited [13-19]. In this article, we report a
hase I study designed to examine the ability of
mifostine to provide cytoprotection against the
RT of melphalan when used at doses beyond those
ermitted with AHSCT alone. t
74ATIENTS AND METHODS
pproval
All patients were treated in compliance with the
eclaration of Helsinki. Institutional review board
pproval was obtained at each institution.
efinitions
RRT was graded by using the Seattle (Bearman)
riteria [20]. Because mucosal RRT was anticipated to
e especially problematic [7,10], it is worthwhile to
etail the criteria for grading this organ system. Grade
RRT is deﬁned as pain, ulceration, or both that does
ot require continuous intravenous narcotics, whereas
he grade II deﬁnition requires the use of continuous
ntravenous narcotics. Grade III RRT is deﬁned as
evere ulceration, mucositis, or both requiring preven-
ative intubation or resulting in aspiration pneumonia
ith or without intubation. Grade IV toxicities are
atal. Although this scale is admittedly not as precise a
easurement of the degree of mucosal RRT as others
21], we were more interested in deﬁning the maxi-
um tolerated dose (MTD) of melphalan in this set-
ing rather than deﬁning a very precise degree of
ucosal RRT. Also, this simple and widely used sys-
em was believed to be reproducible in a multi-insti-
utional setting.
tudy Design
Dose level I began at (or slightly beyond) the
resumed MTD of melphalan by using AHSCT with-
ut amifostine at 220 mg/m2 [8-10]. Subsequent dose
scalations were planned at 20 mg/m2 increments in
ohorts of 4 patients. If no grade III RRT events
ere noted by day 30 after AHSCT, an additional
ohort of 4 patients was entered at the next dose level.
f a single grade III RRT event was noted, 4 addi-
ional patients were entered at that dose, and dose
scalation proceeded only if no additional grade III
RT events (ie, 1 of 8) were noted. The occurrence
f 2 grade III RRT events at a melphalan dose
evel was deemed excessive, and no additional patients
ere entered at that level.
Patients who died sooner than day 30 as a result
f tumor-related or non-RRT complications (eg, pan-
ytopenia) without RRT were deemed ineligible for
etermination of the MTD, and additional patients
ere entered in their place. Also, if a full cohort of 4
atients had been entered at a given level without the
bservation of grade III RRT, but without fol-
ow-up to day 30 in all 4 patients that would permit
ose escalation to the next level, additional patients
ould be entered on a single-patient basis at that level
t the discretion of the principal investigator. Also,
atients were subsequently entered at the MTD to
etter deﬁne toxicity. Thus, more than 4 (or 8) pa-
ients were entered for most melphalan dose levels.
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Amifostine Plus AHSCT and Escalating-Dose Melphalan
Btatistical Analyses
Survival was calculated from the date of AHSCT
o the date of death or the date of last follow-up if
live. Progression-free survival was calculated from
he date of AHSCT to the date of progression or the
ate of last follow-up if no progression had occurred.
vent-free survival was calculated from the date of
HSCT to death or progression, or to the date of last
ollow-up if neither of these had occurred. These
utcomes were calculated by using the method of
aplan and Meier [22].
ligibility
Inclusion criteria were as follows: (1) age 14 to 70
ears; (2) conﬁrmation of primary malignant diagno-
is, recurrence, or both (diagnoses included malignan-
ies commonly treated by AHSCT regimens); (3) dis-
ase status with low curative potential with other
HSCT regimens; (4) absence of a higher-priority
ntrainstitutional AHSCT protocol; (5) Eastern Co-
perative Oncology Group performance status2; (6)
ull recovery from acute toxic effects of prior therapy;
7) acceptable hematologic function and marrow cel-
ularity 20%; (8) acceptable critical organ status,
eﬁned as measured creatinine clearance 60 mL/
in, left ventricular ejection fraction 45% (by mul-
iple-gated acquisition scan or echocardiogram), dif-
usion capacity for carbon monoxide 50% and
orced vital capacity (forced expiratory volume in 1
econd) 60% of predicted, and liver function studies
2 times normal; (9) cumulative anthracycline dose or
ose equivalent 450 mg/m2 of doxorubicin; (10)
uman immunodeﬁciency virus seronegativity; (11)
rst or second AHSCT; and (12) informed consent.
Exclusion criteria were (1) active solid brain me-
astases or malignant meningitis; (2) inability to dis-
ontinue antihypertensive drugs for 24 hours before
he administration of amifostine; and (3) presence of
ny comorbid condition that, in the view of the at-
ending physician, rendered the patient at excessive
isk from anticipated treatment complications.
harmacokinetics
The parameters of area under the curve, t1/2, and
max were obtained in 29 of these patients [23] and
ill be reported separately.
tem Cell Mobilization, Procurement,
anipulation, and Transplantation
Mobilization. Intravenous cyclophosphamide 4.0
/m2 and ﬁlgrastim 10 g/kg/d were recommended
or stem cell mobilization. However, other regimens
ie, other chemotherapy drugs or ﬁlgrastim doses or
lgrastim alone) were used as indicated.
Procurement. Ideally, cytaphereses were continued t
B&MTntil 2.0  106 CD34 cells per kilogram had been
btained. However, patients could be entered with the
resence of lower cell doses [24]. If processing with a
D34 immunoselection device (see below) was used,
greater yield (ie, 5  106/kg) was sought. At 1
enter, if CD34 cell numbers 2.0  106/kg were
btained with cytaphereses, growth factor–primed
arrow [25] was used.
Manipulation, Transplantation, and Supportive Care.
f patients had either prior blood/marrow involvement
ith tumor or other risk factors believed to be asso-
iated with a high risk of tumor cell contamination, it
as recommended (but not required) that the stem
ell product be puriﬁed by CD34 selection with a
ommercially available device. AHSCT was reinfused
ccording to institutional guidelines. Institutional pol-
cy was also followed for routine aspects of post-
HSCT care, including hydration, nutritional supple-
ents, antibiotics, transfusions, and growth factor
upport.
ose Calculations for Amifostine and Melphalan
Doses of amifostine and melphalan were based on
ctual body weight, unless the actual body weight was
125% of the ideal body weight (IBW). For men,
BW is calculated as
IBW 50 kg (2.3 kg [height (in.) 60]) (1)
or women, it is calculated as
IBW 45.5 kg (2.3 kg [height (in.) 60]) (2)
n this case, the body-surface area was calculated by
sing the corrected IBW:
orrected IBW  IBW  0.25
 (actual body weight  ideal body weight)
(3)
rug Formulation and Administration Schedule
Amifostine. Amifostine was supplied as a sterile
yophilized powder mixture in single-use 10-mL vials
ontaining 500 mg of amifostine (anhydrous). Before
ntravenous injection, amifostine was reconstituted
ith 9.7 mL of sterile saline. The reconstituted solu-
ion (amifostine 500 mg/10 mL) is stable up to 5 hours
t room temperature (20°C to 25°C) or up to 24 hours
nder refrigeration (2°C to 8°C). Amifostine solutions
ere prepared in polyvinyl chloride (PVC) bags at
oncentrations ranging from 5 to 400 mg/mL. Ami-
ostine is chemically stable for up to 5 hours when it is
tored at room temperature (25°C) or up to 24 hours
hen it is stored under refrigeration (2°C to 8°C).
All patients received amifostine 740 mg/m2, with
oses calculated to the nearest 10 mg. Two doses of
mifostine were given 24 hours apart after preparation
hat included the discontinuance of antihypertensives,
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4he use of prophylactic dexamethasone and an anti-
metic regimen (usually including a serotonin antag-
nist and additional dexamethasone), recumbency, sa-
ine volume loading, and prophylactic calcium salt
nfusions. Calcium salt was given in an attempt to
void the known complications of hypocalcemia [26].
efore the infusion of amifostine solution was initi-
ted, the intravenous tubing was primed with normal
aline. Amifostine was given over exactly 15 minutes
ith a volumetric pump by 3 institutions and over 5
inutes at another. After the amifostine infusion was
omplete, the line was ﬂushed with normal saline.
Melphalan.Melphalan was reconstituted according
o the manufacturer’s directions. The 50-mg vial was
econstituted with 10 mL of the provided diluent for
ﬁnal concentration of 5 mg/mL. The ﬁnal dose was
laced, undiluted, in a PVC bag and infused over 15
inutes, beginning immediately after the termination
f the amifostine infusion. All melphalan doses were
repared immediately before administration, deliv-
red directly for administration, and calculated to the
earest 1.0 mg. No more than 90 minutes elapsed
etween the time of melphalan vial reconstitution and
ompletion of the infusion.
ESULTS
atient Characteristics and Follow-up
Between December 31, 1997, and December 29,
000, 58 cancer patients were recruited for this trial
rom 4 institutions. Key clinical characteristics are as
ummarized in Table 1. All 21 patients currently alive
ave been followed up for more than 1 year after
HSCT, save for 2 patients who were lost to fol-
able 1. Clinical Characteristics of the 58 Cancer Patients Given
elphalan 220 to 300 mg/m2 Amifostine, and AHSCT
Variable Data
ge, y, median (range) 49 (23-69)
ex (M/F) 22/36
iagnoses
MM/primary amyloidosis 18/2
NHL/HL 15/3
Breast cancer (MBC/HRPBC) 13 (10/3)
AML 5
Ovarian cancer 2
isease status
Early 8
Intermediate 25
Advanced 25
Active disease/remission 46/12
ML indicates acute myelogenous leukemia; AHSCT, autologous
hematopoietic stem cell transplantation; HL, Hodgkin lym-
phoma; HRPBC, high-risk primary breast cancer; MBC, meta-
static breast cancer; MM, multiple myeloma; NHL, non-
Hodgkin lymphoma.ow-up at day 136 and 509. Seventeen additional f
76atients, now dead, were followed up for more than 1
ear. This prolonged follow-up was believed to be
mportant, because the RRT criteria used [20] do not
valuate delayed (ie, day 100 or longer) toxicities
otentially related to RRT.
ctual Melphalan Dose Administered
The median difference between the dose calcu-
ated by using the actual body weight and that given as
orrected IBW was 10% (range, 0% to 19%) at the
elphalan 220 mg/m2 dose, 5% (range, 0% to 10%)
t the 240 mg/m2 dose, nil (range, 0% to 15%) at the
60 mg/m2 dose, 6% (range, 0% to 28%) at the 280
g/m2 dose, and 17% (range, 0% to 18%) at the 300
g/m2 dose. In all 58 patients, calculated versus actual
ose revealed a median discrepancy of 10% (range,
% to 28%). Fourteen patients received the melpha-
an dose calculated from the actual body weight.
mifostine Infusion Toxicity
Many patients developed mild toxicity temporally
elated to the amifostine infusions; in none of these
atients were these symptoms or signs judged severe
nough to interrupt the amifostine infusion. More
peciﬁcally, variable degrees of nausea and emesis
ere noted, but in none was it intractable. Also, no
atient developed hypotension to the degree requiring
nterruption of the infusion. Several patients devel-
ped sneezing, but no glossal edema or other obvious
llergic reactions were seen. Despite the prophylactic
nd, later, therapeutic administration of calcium salts
26], 6 patients developed hypocalcemia that persisted
p to 5 days later; however, hypocalcemia was symp-
omatic in only 1 case.
ematologic Toxicity
Patients with normal blood counts at the initiation
f therapy developed relatively gradual pancytopenia,
ith white blood cell nadirs usually noted on day 5
r later. As indicated in Table 2, hematologic recovery
as generally prompt, despite considerable variations
n CD34 cell dose and institutional use of post-
HSCT hematopoietic growth factor administration.
he median day of absolute neutrophil count recovery
0.5  109/L) was day 13 (range, day 8 to 37).
reedom from the need for platelet transfusions, usu-
lly when a stable, endogenous platelet count of
20.0  109/L was achieved, occurred at a median
f day 15 (range, day 0 to 577 or later) after
HSCT.
Seven patients experienced delayed hematologic
ecovery (deﬁned as recovery of either absolute neu-
rophil count or platelets to the levels noted previ-
usly on day 30 or thereafter). All save 1 of these
atients had at least 1 (and occasionally more) of the
 6ollowing factors: CD34 cell dose of 2.0  10 /kg,
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Barvest after a prior AHSCT, development of second-
ry myelodysplastic syndrome, and early recurrence of
cute myelogenous leukemia. No melphalan dose ef-
ect was noted. Moreover, no late (ie, after initial
ecovery) impairment of hematologic parameters de-
eloped in the absence of obvious factors such as
arrow relapse, development of myelodysplastic syn-
rome, or use of salvage chemotherapy or radio-
herapy.
onhematologic Toxicity (RRT)
General. Six of the 11 patients given melphalan
20 mg/m2 had no RRT as graded by the Seattle/
earman criteria [20]. Of the remaining 47 patients
reated at higher dose levels, 4 experienced no RRT: 2
eceived melphalan 280 mg/m2, and 2 others received
elphalan 300 mg/m2. Of the 48 patients who expe-
ienced RRT, 45 had RRT conﬁned to a single organ
ystem; the mucosa was the (single) involved system in
3. Fatal RRT was observed in 3 patients, as described
elow.
Mucosal Toxicity. As indicated in Figure 1, grade I
r II mucositis developed in 43 of the 53 evaluable
atients; no patient developed grade III mucosal
RT. Moreover, there was no obvious increased in-
idence of grade I versus grade II toxicity at any dose
evel beyond melphalan 220 mg/m2. Four of the 32
atients given the highest melphalan dose levels (ie,
80 and 300 mg/m2) did not have mucosal RRT. For
he 19 patients with grade II mucosal RRT, oropha-
yngeal pain and signs of ulceration and hemorrhage
ecessitated variable degrees of reduction (and usually
omplete cessation) of oral intake and the use of in-
ravenous (often continuous infusion) opioid therapy.
The median onset date of mucosal RRT for all
atients was day 5 (range, day 0 to 10), and
esolution occurred at a median of day 13 (range,
ay 5 to 29). Although higher melphalan doses
nd grade II mucosal RRT were associated with a
lightly more rapid onset and a slightly longer dura-
ion, there was considerable variability and no consis-
able 2. Hematopoietic Toxicity/Recovery Data by Melphalan and CD3
elphalan Dose
(mg/m2)
No.
Patients
CD34  106/kg,
Median (Range)
220 11 3.56 (0.28-31.56)
240 5 5.65 (4.29-26.4)
260 6* 3.55 (1.18-5.13)
280 27† 5.84 (2.22-16.7)
300 9‡ 5.20 (0.35-28.9)
All doses 58 5.19 (0.28-31.56)
NC indicates absolute neutrophil count
One patient died on day 9 without ANC recovery.
One patient with secondary acute myelogenous leukemia failed to
Two patients died on day 12 and 13 of RRT. One had achievent pattern (data not shown). It should be noted that m
B&MThese observations were based on both subjective and
bjective ﬁndings, with relatively fewer patients in
ome cohorts. Moreover, these events were often
raded by different observers. Thus, these data re-
arding onset and resolution of mucosal RRT may be
ess precise than desired.
Similarly, although many patients also developed
iarrhea, we are reluctant to assign an exact incidence
r severity to this RRT, because the degree and in
ome cases even the presence of diarrhea was difﬁcult
o assess. This difﬁculty was due to a number of
actors, including early discharge to the outpatient
etting, the presence of coincident colonic infections
ie, Clostridium difﬁcile) in 10 patients, and the con-
omitant use of medications for other indications that
ay have affected the incidence or severity of diarrhea
ne way or another (eg, the use of metoclopramide for
elayed nausea and use of opioids for oropharyngeal
ain, as described previously). Thus, although many
atients required symptomatic therapy with agents
l Dose
of ANC > 0.5  109/L,
Median (Range)
Day of Last Platelet Transfusion,
Median (Range)
15.0 (10-33) 15.0 (10-33)
13.5 (10-18) 10.0 (10-16)
12.5 (10-12) 20.5 (0-40)
12.0 (9-37) 15 (7-557)
11.0 (8-17) 13.5 (7-180)
13.0 (8-37) 15.0 (0-577)
r and relapsed at day 62.
C recovery; neither achieved platelet recovery.
igure 1. Mucosal regimen-related toxicity in 53 evaluable patients
ho received melphalan doses of 220 to 300 mg/m2, amifostine, and
HSCT. *Includes 1 patient who died on day 9 with grade I4 Cel
Day
recove
ed ANucositis that had not resolved.
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4uch as loperamide, no patient developed grade III
astrointestinal RRT or an “acute abdomen.”
Finally, although bacteremias occurred in 10 pa-
ients, no predominant organism was identiﬁed, and
nly 1 patient’s organism was anaerobic. There were
o obvious correlations between bacteremia, melpha-
an dose, neutrophil recovery, and mucosal RRT (data
ot shown).
ardiotoxicity
As indicated in Table 3, the most frequent non-
ucosal RRT was cardiac; 4 patients developed RRT.
ne patient treated at the melphalan dose of 220
g/m2 developed severe congestive heart failure
without atrial ﬁbrillation or other dysrhythmias) on
ay 28 and died on day 30. This patient had no
istory of cardiac problems but had received prior
hest wall radiotherapy and a cumulative dose of
oxorubicin 600 mg/m2 as treatment for metastatic
reast cancer. A pre-entry nuclear study showed an
jection fraction of only 40%, but she had no other
igns of cardiac dysfunction and was cleared by a
ardiologist. Permission for necropsy was denied.
As also indicated in Table 3, 3 other patients
eveloped cardiac RRT in the form of atrial ﬁbrilla-
ion. One patient without a history of atrial ﬁbrillation
eceived melphalan 280 mg/m2 and developed atrial
brillation on day 15 that resolved spontaneously:
here were no other obvious predisposing factors. A
econd patient developed atrial ﬁbrillation/ﬂutter
hile in the throes of multiorgan failure on day 11
nd died on day 13 of hepatic necrosis with rate-
ontrolled atrial ﬁbrillation. A third patient developed
ntractable atrial ﬁbrillation on day 9 while ill with
neumonia. This patient had a history of atrial ﬁbril-
ation and ultimately died with hemodynamic com-
romise due to dysrhythmia in the setting of multior-
an failure.
epatotoxicity
Two other patients had hepatic RRT, 1 with grade
treated with melphalan 280 mg/m2 and the other
able 3. Nonmucosal RRT, Graded According to the Seattle
Bearman) Criteria [20]
Melphalan Dose
(mg/m2)
Total No.
Patients
Affected
Patients
Organ
System Grade
220 11 1 Cardiac IV
240 5 0 — —
260 6 0 — —
280 27 1 Hepatic I
1 Cardiac II
300 9 2 Cardiac II, IV
1 Hepatic IV
All doses 58 6 — —ith grade IV RRT treated with melphalan 300 mg/ 2
782. The latter patient developed the clinical picture of
eno-occlusive disease of the liver and subsequently
ied of multiorgan failure on day 12. (As described
reviously, controlled atrial ﬁbrillation/ﬂutter was
resent as well.) Histopathology obtained at necropsy
as consistent with hepatic necrosis; there were no
bnormal myocardial ﬁndings.
neumotoxicity
No patient developed lung toxicity. However, 1
atient treated at the melphalan dose of 260 mg/m2
ied on day 19 as a result of pulmonary hemorrhage
fter sudden lysis of extensive lung deposits of lym-
homa. (This patient was coded as a tumor-related
eath and not as pulmonary RRT.)
ephrotoxicity
Although 1 patient was initially graded as grade II
enal RRT, subsequent review indicated that this was
ue to hypovolemia and nephrotoxic antibiotics.
hus, no veriﬁed renal RRT was identiﬁed.
ate Toxicity
Of the 37 patients who survived and were followed
p to day365 or beyond, none developed signiﬁcant
rgan toxicity that could be considered to represent
he sequelae or progression of initial RRT. Also, there
ere no cases of late graft failure, although 1 patient
ith known secondary acute myelogenous leukemia
id not recover counts after AHSCT, was found to be
n relapse at day 62, and died as a result of acute
yelogenous leukemia on day 88. Two extensively
reated non-Hodgkin lymphoma patients, including 1
ho had undergone a prior AHSCT, developed sec-
ndary myelodysplastic syndrome/acute myelogenous
eukemia, which was ultimately fatal in both. Another
atient with known silicosis before AHSCT died of
rogressive respiratory insufﬁciency on day 377 but
ad previously experienced tumor progression. Fi-
ally, 1 patient developed probable progressive mul-
ifocal leukoencephalopathy and was alive but debili-
ated on day 509; subsequently, this patient was lost
o follow-up.
urrent Status
As of January 1, 2003 (or later in some cases), 21
atients were alive, although 2 of these patients were
ost to follow-up at day 136 and 509. As indicated
n Figure 2, their median overall survival was day
742 (range, day 9 to day 1923). The median
vent-free survival was day 248 (range, day 0 to
ay 1638; Table 4 and Figure 3). Fourteen of these
6 patients were continuously progression free.
Of the 27 patients treated at the melphalan dose of
280 mg/m , 8 were alive (5 disease free) at day1449,

t
a
d
t
t
s
c
g
(
D
f
c
c
c
n
c
s
o
s
R
c
w
R
t
w
s
w
f
c
c
a
p
p
a
r
m
a
vival a
T
M
H
Amifostine Plus AHSCT and Escalating-Dose Melphalan
B1351, 926, 906, and 824. Of the 9 treated at
he melphalan dose of 300 mg/m2, 5 were disease free
t day 1234, 1221, 1183, 1075, and 1012.
Conversely, as of the same date, 37 patients were
ead, including 30 who died directly as a result of
umor progression. Others died due to RRT (n  3),
umor-related causes other than progression (n  1),
econdary myelodysplastic syndrome (n  2), and
omplications after a planned nonmyeloablative allo-
eneic hematopoietic stem cell transplantation
n  1).
ISCUSSION
Effective cytoprotection against RRT may be use-
ul in the AHSCT setting in any of several ways. First,
ytoprotection could be used to diminish the RRT of
urrent AHSCT regimens [13-19]. Although most
urrent AHSCT regimens do not have a high intrinsic
onrelapse mortality [27], even moderate RRT causes
onsiderable morbidity and increases cost [28]. Also,
ome patients may be excluded from AHSCT because
Figure 2. Overall sur
able 4. Current Progression-Free Survivors as of January 1, 2003
elphalan Dose
(mg/m2)
Total No.
Patients D
220 1 HL
240 1 MBC
260 1 AML
280 6 4 myeloma
300 5 3 NHL, 2 m
Total 14
L indicates Hodgkin lymphoma; HRPBC, high-risk primary br
leukemia; MBC, metastatic breast cancer.
B&MTf comorbid disease believed to increase the risk of
evere RRT [29]. Effective cytoprotection against
RT used in this manner would directly represent a
onsiderable improvement in tolerability and cost but
ould be likely to improve survival only indirectly.
Alternatively, effective cytoprotection against
RT could be used to permit additional dose escala-
ion of existing cytotoxic agents or regimens, ideally
ith lower (but, more realistically, similar) rates and
everity of RRT compared with current regimens used
ithout cytoprotection. We chose the latter approach
or this study to permit a fuller exploration of the
hemotherapy dose-response curve in certain human
ancers.
For this purpose, selection of an optimal cytotoxic
gent or regimen is critical. The alkylating agent mel-
halan was selected for a variety of reasons. First,
reclinical work from a number of years ago revealed
steep, log-linear dose effect of melphalan [2] and
evealed that augmented doses sometimes overcame
elphalan resistance. Other early studies revealed that
mifostine modiﬁed melphalan-induced gut toxicity in
s of January 1, 2003.
s Respective Follow-up (day)
1638
1510
1554
PBC, 1 HL 1449, 926, 916, 906 1351 834
a 1221, 1183, 1075 1234, 1012
Median, 1208 (range, 834 to 1638)
ncer; NHL, non-Hodgkin lymphoma; AML, acute myelogenousiagnosi
, 1 HR
yelom
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4odents [30]. Next, melphalan has a rapid plasma
learance [8], a feature that matches well with amifos-
ine pharmacokinetics [31] and the presumed need to
ave the activated form of amifostine (WR-1065) in
issues during drug exposure [32]. Clinically, the rel-
tively predictable RRT found at the presumed MTD
f melphalan alone (ie, 200-220 mg/m2) is usually
onﬁned to the mucosa [8-10], thus potentially limit-
ng the number of tissues requiring cytoprotection.
inally, melphalan has known activity against a num-
er of malignancies in either conventional doses or
hose requiring hematologic growth factor, AHSCT
upport, or both [6].
Most investigators consider the MTD of melpha-
an in the AHSCT setting to be 200 mg/m2 [8] or
erhaps 220 mg/m2 [10]. Moreover, 240 mg/m2 seems
o be the maximum melphalan dose that has been
eported for clinical use [33]. This last experience was
n the allogeneic hematopoietic stem cell transplanta-
ion setting, which is obviously more complicated to
nterpret and was associated with considerable nonre-
apse mortality; RRT was not precisely reported. A
ase report describes an accidental overdose of 290
g/m2 of melphalan that produced death due to an
nspeciﬁed cardiac dysrhythmia [34].
We used amifostine as the cytoprotective of choice
ecause of its preclinical [30,32] and clinical utility
ith conventional-dose therapy, its broad spectrum of
rgan cytoprotection (especially the mucosa in this
etting), its manageable intrinsic toxicity, its lack of
rug interaction with melphalan, and its ready avail-
bility [11,31,35]. Moreover, preclinical data suggest
ot only a selective protective effect, but also a possi-
le enhancement of melphalan genotoxicity [36], al-
hough these data were not known when this trial was
Figure 3. Progression-frenitiated. a
80We have apparently increased the dose of melpha-
an that can be given with the addition of amifostine
nd AHSCT. We are somewhat cautious in this in-
erpretation, however, because of uncertainty as to the
recise MTD of melphalan without amifostine with
HSCT [8-10,33], the variable dose/schedule
chemes reported for both agents [8-11,35,37], the
ariable methods of calculating dose in different stud-
es, heterogenous melphalan pharmacokinetics [8], cu-
ulative tissue damage from prior therapy, and per-
aps other factors. That said, whereas 280 mg/m2 is
ikely the MTD of melphalan in this setting, the
ariability of the RRT encountered at the melphalan
00 mg/m2 dose (as well as the relatively uncompli-
ated courses of most of the patients treated at the
elphalan 300 mg/m2 dose) make us less certain that
his is the case. Additional studies would be helpful,
lthough it would be difﬁcult to conﬁrm these ﬁndings
n a randomized, placebo-controlled trial.
As expected, mucosal RRT was the chief problem
ncountered. However, and as noted previously, mu-
osal RRT was managed successfully at even the mel-
halan 300 mg/m2 dose level and was not the DLT,
nd we do not believe that we have clearly deﬁned the
LT. One possibility is that it may be cardiac RRT in
he form of atrial ﬁbrillation. Atrial ﬁbrillation has
een reported in the literature in the AHSCT setting
38,39] with melphalan doses of 200 to 220 mg/m2. In
ur series, atrial ﬁbrillation was observed only with
elphalan doses 280 mg/m2—the doses given to
ost patients. However, it must be noted that 2 of
hese patients had multiple ongoing problems in
hich atrial ﬁbrillation could have been expected,
aking this determination difﬁcult.
In any case, because we and others have observed
al as of January 1, 2003.trial ﬁbrillation in patients without a history of car-
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Biac problems, patients so treated should be closely
bserved for this complication. Moreover, those with
history of dysrhythmia should at least be considered
or prophylaxis or cardiac monitoring. Whether phar-
acologic suppression of atrial ﬁbrillation would al-
ow additional dose escalation is unclear, but it is
ertainly possible, given it represents a less ﬁxed RRT
han, say, hepatic necrosis.
Another possibility is that the DLT may be he-
atic. Although noted in combinations with melpha-
an, signiﬁcant hepatotoxicity with single-agent mel-
halan therapy is rare [8]. In this series, severe
epatotoxicity occurred in only 1 patient (of 8) who
as given melphalan 300 mg/m2. Nonetheless, it was
atal in this patient, who had no other obvious risk
actors, such as underlying hepatic disease.
As indicated in Table 5, our study adds to a rela-
ively small and only recently published experience
ith amifostine in the AHSCT setting [13-19]. As
ndicated, results have been variable; some studies
ave indicated positive effects of amifostine, whereas
thers have been neutral. Of the published studies
vailable, perhaps the most notable is that of Hart-
ann et al. [17], because of its use of a randomized
rial design. In this study, 40 solid-tumor patients
ere randomized to treatment with a combination
hemotherapy regimen (not including melphalan)
ith AHSCT, with or without amifostine. Amifos-
ine-treated patients had reductions in acute RRT,
oth mucosal and renal; there was also a mild reduc-
able 5. A Brief Summary of Published Data Regarding Amifostine an
Study
Trial
Type
No.
Patients
(Control)
Chemotherapy (mg/m
 Doses
ingle-agent melphalan
Capelli [13] HC 35 (33) MEL—unspecified (alone 
 “other” (n  13)
Jantunen [19] HC 10 (10) MEL 200
Thieblemont [18] PNR 21 (20) MEL 200
ombination chemotherapy
Renner [16] HC 14 (24) MEL, CBDCA, VP16—213
Hartmann [17] PR 40 CBDCA 500  3; IFOS 40
3; VP16 500  3
Cronin [15] ST 2 VP16 750  3 CBDCA 70
Chauncey [14] HC 21 (67) BU 4 mg/kg  4 TSPA 25
2 MEL 50  2
C indicates historical control; PR, prospective, randomized; PN
busulfan; CBDCA, carboplatin; MEL, melphalan; IFOS, ifosfamion in hematologic toxicity. a
B&MTPerhaps of more relevance to this study, 3 prior
tudies [13,18,19] have reported on the use of high-
ose melphalan with amifostine and AHSCT. One
tudy used melphalan alone; the others used melpha-
an plus other drugs. All used melphalan 200 mg/m2.
ll reported reduced RRT, although Jantunen et al.
19] did not believe that the reductions were of a
igniﬁcant magnitude.
Although it is beyond the scope of this article to
ully analyze these results, it must be noted that there
as considerable heterogeneity of tumor type, prior
herapy, speciﬁcs of chemotherapy (eg, agent, dose,
nd schedule), and speciﬁcs of amifostine dosing and
dministration. It is probably safest to say that ami-
ostine was not uniformly effective in these cases;
urther studies are needed to better assess the effect of
mifostine in this setting. However, this statement
hould be considered in light of the fact that amifos-
ine—or any cytoprotective agent—is most unlikely to
e universally effective. Although our treatment
chedule was chosen on the basis of both experimental
32,40,41] and clinical [37] data, comparative data are
imited, and an optimal dose schedule is unknown.
oreover, as more is learned about amifostine
40,42], we realize that it is possible not only that we
id not use this agent optimally, but also that the ways
n which amifostine is used with conventional-dose
herapy are different in the high-dose chemotherapy
ituation.
Of course, even if a higher dose of melphalan is
-Dose Chemotherapy/AHSCT
mifostine (mg/m2)
 Doses Toxic Effects Response/Survival
740  1 Hematologic ND; emesis,
mucositis and diarrhea all
decreased in amifostine-
treated patients
Improved survival at
1 y in amifostine-
treated patients
910  1 Hematologic ND; mucositis
ND; diarrhea slightly
decreased
NS
740  1 Hematologic ND; mucositis
decreased; delayed emesis
ND
— Hematologic ND; renal ND;
mucosal decreased
NS
910  3 Hematologic slightly
decreased; mucosal
decreased; renal slightly
decreased
NS
1000  3 Hematologic decreased;
mucosal decreased
NS
910  4 Hematologic ND; mucosal
ND; hepatic ND; renal
slightly decreased
NS
spective, nonrandomized; ST, sequential therapy evaluation; BU,
PA, thiotepa; VP16, etoposide; NS, not stated; ND, no difference.d High
2) A
10)
00 
0  3
0 
R, pro
ide; TSchievable with the use of amifostine, this type of trial
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4oes not demonstrate the desired result of an im-
roved antitumor effect (or, in a broader sense, the
herapeutic index). Although response determinations
re not part of classic phase I studies, this study dif-
ered in several aspects from typical phase I studies,
nd we believe that it is important to note responses.
n brief, and as indicated in Table 4, tumor responses
ere noted in all histologic types and at all doses;
hese results are at least consistent with the hypothesis
hat augmented cell kill is achieved with these doses of
elphalan above what has been given historically
ithout amifostine. Obviously, we have not offered
eﬁnitive proof, and further phase II testing is
eeded.
Limited clinical data indicate that improved out-
omes may be possible with such efforts. In addition
o the work by Clift et al. [5] noted previously, recent
ork in the intensiﬁcation of current conditioning
egimens with the use of dose augmentation via tar-
eted radioimmunotherapy as the key component of
yeloablation has produced provocative results [43].
o this end, our use of amifostine may be seen as a
arallel effort or, more arguably, as an adjunct to these
rials. Also, there is no reason to assume that an
mifostine-augmented dose of melphalan, with or
ithout amifostine-augmented doses of other agents,
ould not be used in combination.
We have thus provided preliminary clinical infor-
ation that current barriers of RRT in the AHSCT
etting can be breached by the use of cytoprotective
gents such as amifostine. Future studies, possibly
iffering from classic chemotherapy designs [44], us-
ng this or other cytoprotective schemata, may be
erformed to further explore the dose effect of avail-
ble and perhaps newer cytotoxic agents at augmented
oses. In addition, there is no reason to assume that
mifostine alone would prove to be optimal, and
ewer cytoprotective agents, with or without amifos-
ine—but likely in combination—may be anticipated.
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